Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

NCT02592707 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT02592707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02592707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Lead sponsor
Ipsen
Phase
Phase 1/2
Overall status
Terminated
Start date
March 6, 2017
Completion date
February 22, 2022
Enrollment
40 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors